Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2

Status

Completed 5Terminated 4Active not recruiting 4Recruiting 1

Sponsor Class

INDUSTRY 5OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 2Tumor-Agnostic 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Ovarian Neoplasms 1Non Hematologic Cancers 1Neoplasms 1Lung Neoplasms 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × INDUSTRY × defactinib × Clear all
NCT04620330 2024-01-12

RAMP202

Verastem, Inc.

Phase 2 Completed
90 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01778803 2017-05-17

Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer

Verastem, Inc.

Phase 1 Completed
22 enrolled
Gynecologic

Ovarian Neoplasms

NCT01951690 2017-04-13

Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer

Verastem, Inc.

Phase 2 Completed
55 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01943292 2017-03-09

Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies

Verastem, Inc.

Phase 1 Completed
9 enrolled 7 charts

Non Hematologic Cancers

NCT00787033 2017-01-25

B0761001

Verastem, Inc.

Phase 1 Completed
46 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡